علاج سرطان الدم الليمفاوي المزمن مع تقدم المرض على مثبط BTK التساهمي

References

1. Patients whose CLL progresses on a covalent BTKi should be offered either a venetoclax-based regimen, irrespective of TP53 status (GRADE 1B) or Pirtobrutinib (Grade 1B, EMA, MHRA approved).
2. Idelalisib–rituximab remains an option for patients who are refractory to BTKi-and BCL2i-based treatment, or for whom these treatments are unsuitable (GRADE 2B).